Narrow search
Showing 1 - 10 of 1,437
Cover Image
Decision Analysis of Histamine H2-Receptor Antagonist Maintenance Therapy Versus Helicobacter pylori Eradication Therapy: A Randomised Controlled Trial in Patients with Continuing...
Tavakoli, Manouche; Prach, Andrzej T.; Malek, Mo; … - In: PharmacoEconomics 16 (1999) 4, pp. 355-365
eradication therapy using an omeprazole/amoxicillin/metronidazole regimen (or omeprazole/clarithromycin if allergic to penicillin …
Persistent link: https://www.econbiz.de/10005243190
Cover Image
Economic Evaluation of Antibacterials in the Treatment of Acute Sinusitis
Laurier, Claudine; Lachaine, Jean; Ducharme, Murray - In: PharmacoEconomics 15 (1999) 1, pp. 97-113
costs when compared with the other antibacterials. Low dosages of clarithromycin and azithromycin followed amoxicillin in …. Interventions: The antibacterials studied were amoxicillin, amoxicillin/clavulanate, azithromycin, cefaclor, cefuroxime axetil and … clarithromycin. Main outcome measures and results: The main outcome measured was the proportion of patients showing resolution or …
Persistent link: https://www.econbiz.de/10004990334
Cover Image
Cost Effectiveness of Helicobacter pylori Eradication Therapies in Patients with Duodenal Ulcer: An Analysis of Triple Therapy Versus Two Dual Therapy Alternatives
Tennvall, Gunnel R.; Norinder, Anna; Ohlin, Bo - In: PharmacoEconomics 16 (1999) 3, pp. 297-306
clarithromycin versus 2 dual therapies (lansoprazole or omeprazole, each with amoxicillin) in the eradication of Helicobacter pylori … therapy with lansoprazole, amoxicillin and clarithromycin is more cost effective than dual therapy because of a higher …
Persistent link: https://www.econbiz.de/10005449162
Cover Image
Counting the Costs of Drug-Related Adverse Events
White, T. Jeffrey; Arakelian, Annet; Rho, Jay P. - In: PharmacoEconomics 15 (1999) 5, pp. 445-458
hospitals, exceeding deaths caused by pneumonia and diabetes. The economic burden resulting from drug-related morbidity and …
Persistent link: https://www.econbiz.de/10005449050
Cover Image
The Clinical and Economic Potential of Cyclosporin Drug Interactions
Martin, Jill E.; Daoud, A. Jamal; Schroeder, Timothy J.; … - In: PharmacoEconomics 15 (1999) 4, pp. 317-337
blockers, diltiazem, verapamil and nicardipine; and the macrolide antibacterials, erythromycin and related compounds. Although …
Persistent link: https://www.econbiz.de/10005449102
Cover Image
Cefotaxime: A Pharmacoeconomic Review of its Use in the Treatment of Infections
Plosker, Greg L.; Foster, Rachel H.; Benfield, Paul - In: PharmacoEconomics 13 (1998) 1 Part 1, pp. 91-106
pneumonia, complicated urinary tract infections and bacteraemia. In general, comparative trials have shown that cefotaxime has … number of detailed pharmacoeconomic analyses of cefotaxime have been conducted. One analysis, in patients with pneumonia or …
Persistent link: https://www.econbiz.de/10005449105
Cover Image
Chlamydia trachomatis in Adolescents and Adults: Clinical and Economic Implications
Marra, Carlo A.; Patrick, David M.; Reynolds, Robert; … - In: PharmacoEconomics 13 (1998) 2, pp. 191-222
The aim of this article is to provide an overview of the epidemiology, diagnosis, screening and pharmacotherapy of Chlamydia trachomatis infections in adolescents and adults, together with a critical review of economic studies published on this topic. C. trachomatis continues to produce enormous...
Persistent link: https://www.econbiz.de/10005449226
Cover Image
Cost Effectiveness of Prophylaxis for Opportunistic Infections in AIDS: An Overview and Methodological Discussion
Freedberg, Kenneth A.; Paltiel, A. David - In: PharmacoEconomics 14 (1998) 2, pp. 165-174
Dramatic progress has recently been made in defining the pathogenesis and treatment of HIV infection. For the first time in the history of the AIDS epidemic, clinicians have at their disposal an understanding of the replication kinetics of HIV, reliable assays to measure viral load, an...
Persistent link: https://www.econbiz.de/10005449227
Cover Image
Socioeconomics of a Global Leprosy Eradication Programme
Naik, Sharad S.; Ganapati, Ramaswamy - In: PharmacoEconomics 13 (1998) 6, pp. 677-686
In the absence of evidence in the literature on cost factors in the management of leprosy, a reference is made to the sporadic attempts to study costs of case detection and treatment. Such studies indicate that in the currently declining phase of leprosy endemicity, employing a conventionally...
Persistent link: https://www.econbiz.de/10005404853
Cover Image
Meropenem: A Pharmacoeconomic Review of its Use in Serious Infections
Holliday, Stephen M.; Benfield, Paul - In: PharmacoEconomics 13 (1998) 3, pp. 359-377
Meropenem is a carbapenem antibiotic which is active against the majority of aerobic and anaerobic bacteria implicated in serious infections. Its therapeutic efficacy in a wide range of serious infections is similar to that of imipenem/cilastatin and standard combination drug regimens. Hence,...
Persistent link: https://www.econbiz.de/10005590296